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AfricaThe global acquired immunodeﬁciency syndrome (AIDS) pandemic is thought to have arisen by the
transmission of human immunodeﬁciency virus (HIV-1)-like viruses from chimpanzees in southeastern
Cameroon to humans. TRIM5α is a restriction factor that can decrease the susceptibility of cells of particular
mammalian species to retrovirus infection. A survey of TRIM5 genes in 127 indigenous individuals from
southeastern Cameroon revealed that approximately 4% of the Baka pygmies studied were heterozygous for a
rare variant with a stop codon in exon 8. The predicted product of this allele, TRIM5 R332X, is truncated in the
functionally important B30.2(SPRY) domain, does not restrict retrovirus infection, and acts as a dominant-
negative inhibitor of wild-type human TRIM5α. Thus, some indigenous African forest dwellers potentially
exhibit diminished TRIM5α function; such genetic factors, along with the high frequency of exposure to
chimpanzee body ﬂuids, may have predisposed to the initial cross-species transmission of HIV-1-like viruses.© 2009 Elsevier Inc. All rights reserved.Introduction
The primate immunodeﬁciency viruses include the human
immunodeﬁciency virus type 1 and type 2 (HIV-1 and HIV-2,
respectively) and simian immunodeﬁciency virus (SIV). Simian
immunodeﬁciency viruses infect many of the feral chimpanzee and
monkey species indigenous to various parts of Africa. (Allan et al.,
1991; Apetrei et al., 2005; Bibollet-Ruche et al., 2004; Jolly et al., 1996;
Souquière et al., 2001; Tomonaga et al., 1993; Santiago et al., 2002,
2005). SIVsm in sooty mangabeys in West Africa is closely related to
HIV-2, supporting the hypothesis that HIV-2 arose by transmission of
these viruses from monkeys to humans (Gao et al., 1992; Santiago et
al., 2005; Chen et al., 1996, 1997; Lemey et al., 2003; Marx et al., 1991;
Peeters et al., 1994). Although HIV-2 infection can result in acquired
immunodeﬁciency syndrome (AIDS) in humans, the major cause of
AIDS is HIV-1. Phylogenetically, HIV-1 is classiﬁed into a Major (M)ll rights reserved.Group, an Outlier (O) Group and the non M-non O (N) Group (Lemey
et al., 2004; Ayouba et al., 2000, 2001; Kuiken et al., 2008). HIV-1
Group M variants, responsible for the vast majority of AIDS cases
globally, have been further subdivided into phylogenetically dis-
tinct clades that differ in prevalence according to geographic region
(Kuiken et al., 2008).
Several pieces of evidence support a west central African origin for
HIV-1. Firstly, HIV-1-like viruses in feral chimpanzees (SIVcpz), gorillas
and cercopithecine monkeys have been identiﬁed in Cameroon (Van
Heuverswyn and Peeters, 2007; Van Heuverswyn et al., 2006, 2007;
Nerrienet et al., 2005; Courgnaud et al., 2003; Keele et al., 2006; Corbet
et al., 2000; Gao et al., 1999). Secondly, signiﬁcant HIV-1 genetic diver-
sity exists among viruses isolated from humans in central Africa,
indicating the presence of the virus for a long period of time relative to
other regions (Peeters et al., 2003; Worobey et al., 2008; Vergne et al.,
2003; Konings et al., 2006; Zhong et al., 2003). For example, indivi-
duals from rural villages in Cameroon are infected with HIV-1 from
diverse clades and often harbor a number of circulating recombinant
forms indicative of multiple infections (Vergne et al. 2003; Konings et
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onlywithHIV-1, but alsowith humanT-cell leukemiaviruses (HTLV-III,
HTLV-IV), simian foamy virus, hepatitis C virus and GB virus C (GBV-C)
in individuals in rural Cameroon (Konings et al, 2006; Switzer et al,
2006; Wolfe et al, 2004; Njouom et al, 2003; Kondo et al, 1997;
Torimiro et al., unpublished data). Thirdly, rural populations in west
central Africa are frequently exposed to the body ﬂuids of non-human
primates through hunting, butchering and keeping of pets (Hahn et al.,
2000). The Baka pygmies are hunter-gatherers of southwestern
Cameroon (Fig. 1) whose semi-nomadic lifestyle has persisted, largely
unchanged, for thousands of years. The repeated exposure of these
forest-dwelling people to the body ﬂuids of non-human primates mayFig. 1. Geographic location of the Baka forest people. The region of Africa highlighted in the bo
Baka people constitute an ethnic group inhabiting the rain forest of southeastern Cameroon, n
The Baka pygmies number from 5000 to 28,000 individuals.have created circumstances favorable to the initial transmission of
HIV-1-like viruses from chimpanzees to a small number of humans.
Once introduced into the human host, HIV-1 diverged from SIVcpz,
presumably allowing improved replication and spread in the human
population.
A major barrier to cross-species transmission of retroviruses is
mediated by the TRIM5α protein (Bieniasz, 2003; Hatziioannou et al.,
2003; Hofmann et al., 1999; Stremlau et al., 2004). Variants of TRIM5α
in different primate species block the early, post-entry phase of
infection of cells by particular retroviruses (Hatziioannou et al., 2004;
Keckesova et al., 2004; Song et al., 2005b; Perron et al., 2004; Yap et al.,
2004). For example, the TRIM5α protein of rhesus monkeys restrictsx in the inset is shown, with the range of the Baka pygmy population shaded green. The
orthern Republic of Congo, northern Gabon and southwestern Central African Republic.
Fig. 2. The TRIM5hu R332X protein. The human TRIM5α protein is shown, with the
domains and interdomain linkers (L1 and L2) labeled (B2 = B-box 2; CC = coiled coil).
The variable (v1–v4) regions of the B30.2(SPRY) domain are shown. The predicted
sequence of the carboxyl terminus of the TRIM5hu R332X protein is shown beneath the
wild-type TRIM5αhu sequence.
Fig. 3. Expression of the human TRIM5 variants in canine epithelial cells. Cf2Th cells
were transduced with either the empty LPCX vector or the LPCX vector expressing wild-
type (wt) TRIM5αhu-HA. Some of the cells were subsequently transduced with the gene
encoding TRIM5hu R332X-V5 using the Viral Power system (Invitrogen). The results
with two independent cultures (cl 1 and cl 2) of the Cf2Th cells coexpressing wt
TRIM5αhu-HA and TRIM5hu R332X-V5 proteins are shown. Cell lysates were Western
blotted and probed with antibodies directed against either the HA epitope tag (top
panel) or the V5 tag (lower panel).
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TRIM5α (TRIM5αhu) is less potent at suppressing HIV-1 or SIVcpz
(Hatziioannou et al. 2004; Keckesova et al., 2004; Stremlau et al., 2004;
Yap et al. 2004; Kratovac et al., 2008). On the other hand, TRIM5αhu
more potently restricts infection by the N-tropic murine leukemia
virus (N-MLV) than TRIM5αrh (Hatziioannou et al. 2004; Keckesova et
al., 2004; Perron et al., 2004; Song et al., 2005b; Yap et al., 2004).
TRIM5 is a member of a family of proteins that contain a tripartite
motif, hence the designation TRIM (Reymond et al., 2001). TRIM
proteins have also been called RBCC proteins because the tripartite
motif includes a RING domain, B-box 2 domain and coiled coil domain.
TRIM proteins exhibit the propensity to assemble into cytoplasmic or
nuclear bodies (Reymond et al., 2001). Many cytoplasmic TRIM
proteins contain a C-terminal B30.2 or SPRY domain. Differential
splicing of the TRIM5 primary transcript gives rise to the expression of
several isoforms of the protein product. The TRIM5α isoform is the
largest product (∼493 amino acid residues in humans) and contains
the B30.2(SPRY) domain. The B30.2(SPRY) domain of rhesus monkey
TRIM5α is essential for recognition of the retroviral capsid and for anti-
HIV-1 activity (Stremlau et al., 2004; Perez-Caballero et al., 2005; Kar
et al., 2008; Langelier et al., 2008).Moreover, the difference in the anti-
HIV-1 potency of rhesus and humanTRIM5α proteins is determined by
variable regions within the B30.2(SPRY) domain (Song et al., 2005a;
Sawyer et al., 2005; Perez-Caballero et al., 2005; Stremlau et al., 2005;
Yap et al., 2005). The decreased potency of human TRIM5α in
restricting HIV-1, for example, is due to the presence of arginine 332
in the v1 variable loop of the B30.2(SPRY) domain (Li et al., 2006; Yap
et al., 2005). This arginine residue decreases the afﬁnity of human
TRIM5α for the HIV-1 capsid (Li et al., 2006). TRIM5α binding to the
retroviral capsid has been shown to lead to accelerated capsid
uncoating, a process facilitated by the TRIM5α RING and B-box 2
domains (Stremlau et al., 2006; Perron et al., 2007; Diaz-Griffero et al.,
2007a,b, 2008; Li and Sodroski, 2008).
Interspecies differences in primate TRIM5α proteins dictate the
potency of restriction against particular retroviruses (Hatziioannou et al.
2004; Keckesova, Ylinen and Towers, 2004; Song et al., 2005b; Stremlau
et al., 2004, 2005; Yap et al. 2004; Kratovac et al., 2008). Considerable
intra-species variation in the TRIM5α proteins of primates has also been
documented (Liao et al., 2007; Newman et al., 2008; Brennan et al.,
2008; Virgen et al., 2008; Wilson et al., 2008). In most reported studies,
common polymorphisms in the coding exons of human TRIM5were not
found to exert signiﬁcant effects on the clinical progression of HIV-1
infection (Speelmon et al., 2006; Javanbakht et al., 2006; Goldschmidt et
al., 2006; Sawyer et al., 2006; Nakayama et al., 2007; van Manen et al.,
2008). One common nonsynonymous SNP (R136Q) exhibited an
increased frequency among HIV-1-infected subjects relative to exposed
seronegative persons, hinting that it may be linked to increased
acquisition of infection (Speelmon et al., 2006). Moreover, some less
common non-coding polymorphisms in African Americans have been
associatedwith increases in susceptibility toHIV-1 infection (Javanbakht
et al., 2006). The mechanism and importance of these potential
regulatory polymorphisms require further investigation.
Here, we report the results of a survey of TRIM5 genotypes in
indigenous Africans living in rural southeastern Cameroon, where
HIV-1 infection in humans likely originated through contact withSIVcpz-infected chimpanzees (Gao et al., 1999; Nerrienet et al., 2005;
Van Heuverswyn et al., 2007; Van Heuverswyn and Peeters, 2007;
Santiago et al., 2002; Corbet et al., 2000; Keele et al., 2006). In Baka
pygmies, we identify a rare TRIM5 allele that is predicted to encode a
truncated TRIM5α protein defective for retrovirus restriction. The
truncated TRIM5 variant exhibits dominant-negative effects on the
wild-type TRIM5α protein. Thus, some African forest dwellers, whose
lifestyle results in frequent exposure to chimpanzee and other non-
human primate body ﬂuids, may possess lower-than-normal TRIM5-
mediated retrovirus restriction activity.
Results
A human TRIM5 allele encoding a truncated protein
To examine the diversity of TRIM5 within a population of
individuals in central Africa, genomic DNA was prepared from the
PBMC of 127 subjects from Cameroon. This cohort included 95 Baka
pygmies and 32 non-pygmies. The complete TRIM5 exon 8, which
encodes the B30.2(SPRY) domain of TRIM5α, was resequenced. A rare
mutation that speciﬁes a premature stop codon (TGA) replacing the
CGA codon for arginine 332 of TRIM5α was observed in four
heterozygotes, all Baka pygmies from the same study site. Thus, 4.2%
of the sampled Baka pygmies are heterozygous for this allele, with an
allele frequency of 2.1% in this group. The allele is predicted to encode
a truncated TRIM5α protein (R332X) missing 83% of the B30.2(SPRY)
domain (Fig. 2); the other TRIM5 isoforms, TRIM5γ and TRIM5δ,
should not be affected by this mutation.
Anti-retroviral activity of TRIM5hu R332X
The TRIM5α B30.2(SPRY) domain is essential for retrovirus
restriction (Stremlau et al., 2004; Perez-Caballero et al., 2005).
Furthermore, arginine 332 in the v1 variable region is a determinant
of anti-HIV-1 potency (Li et al., 2006; Yap et al., 2005). These
observations suggest that the truncated TRIM5hu R332X protein is
probably defective for retrovirus inhibitory activity. To test this, Cf2Th
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TRIM5αhu-HA, TRIM5hu R332X-V5, or both wild-type TRIM5αhu-HA
and TRIM5hu R332X-V5. These proteins have C-terminal HA or V5
epitope tags. Two independent cell lines expressing both TRIM5
variants were established. Cf2Th cells were used for these experi-
ments because dogs do not express a functional TRIM5 protein
(Sawyer et al., 2007), thus allowing an assessment of the human
TRIM5 phenotypes in a clean background. The wild-type TRIM5αhu
protein was expressed at comparable levels in the control cells and in
each of the independent clones in which TRIM5hu R332X-V5 was also
expressed (Fig. 3). The TRIM5hu R332X-V5 protein was expressed at
higher levels in the control LPCX cells than in the cells expressing the
wild-type TRIM5αhu-HA protein. The expression of the wild-type
TRIM5αhu-HA protein may have decreased the efﬁciency of transduc-
tion of the cells by the lentivirus vector expressing TRIM5hu R332X-V5.Fig. 4. Susceptibility of cells expressing human TRIM5 variants to retrovirus infection.
Cf2Th cells transduced with the empty LPCX vector or expressing the indicated TRIM5hu
variants were incubated with various amounts of recombinant HIV-1, B-MLV or N-MLV
expressing GFP. The results with two independent cultures (1 and 2) of the cells
coexpressing the wt and R332X variants of TRIM5 are shown. Infected, GFP-positive
cells were counted by FACS. The results of a typical experiment are shown. Similar
results were obtained in three independent experiments.The susceptibility of the Cf2Th cells expressing the TRIM5hu
variants to retrovirus infection was assessed. The cells were exposed
to increasing concentrations of recombinant HIV-1, B-MLV and N-MLV
expressing GFP. Forty-eight hours later, the level of infection achieved
was assessed by FACS analysis (Fig. 4). Relative to the control cells
transduced with the empty LPCX vector, the cells expressing only
wild-type TRIM5αhu were less infectible by HIV-1. This result is
consistent with previous reports demonstrating that TRIM5αhu
partially restricts HIV-1 infection (Stremlau et al., 2004, 2005;
Perez-Caballero et al., 2005; Sawyer et al., 2005). By contrast, HIV-1
infectionwas not inhibited in cells expressing TRIM5hu R332X. Neither
was HIV-1 infection affected in the cells expressing both wild-type
TRIM5αhu and TRIM5hu R332X proteins. Apparently, the coexpression
of TRIM5hu R332X diminishes the partial HIV-1-restricting ability of
the wild-type TRIM5αhu protein.
As expected (Perron et al., 2004; Hatziioannou et al., 2004;
Keckesova et al., 2004; Yap et al., 2004), the cells expressing the wild-
type TRIM5αhu protein were very resistant to N-MLV infection. No
inhibition of N-MLV infection was observed for the TRIM5hu R332X
protein. Compared with cells expressing only the wild-type TRIM5αhu
protein, cells expressing both wild-type TRIM5αhu and TRIM5hu
R332X proteins exhibited less restriction of N-MLV infection. Thus, for
both N-MLV and HIV-1 infections, wild-type TRIM5αhu is a less
efﬁcient restriction factor when TRIM5hu R332X is coexpressed.
None of the TRIM5 variants tested here affected the efﬁciency of B-
MLV infection. This indicates the speciﬁcity of the inhibitory effects
observed for HIV-1 and N-MLV.
Co-localization and association of wild-type TRIM5αhu and
TRIM5hu R332X
The above results suggest that TRIM5hu R332X can exert some
dominant-negative effects on retroviral restriction by wild-type
TRIM5αhu. As both proteins retain all of the TRIM5 regions shown to
be sufﬁcient for dimerization (Javanbakht et al., 2006), we examined
the colocalization and association of these TRIM5 variants. Wild-type
TRIM5αhu and TRIM5hu R332X colocalized in the cytoplasm of cells
coexpressing these proteins; the TRIM5 proteins exhibited a speckled
pattern superimposed on a diffuse staining of the cytoplasm (Fig. 5A).
The wild-type TRIM5hu protein was coprecipitated with the TRIM5hu
R332X-V5 protein in coexpressing cells (Fig. 5B). Thus, the wild-type
TRIM5αhu and TRIM5hu R332X proteins colocalize and associate,
consistent with the observed dominant-negative effects.
Discussion
The existence of SIVcpz phylogenetically related to HIV-1 Group M
in chimpanzees in Cameroon (Santiago et al., 2002; Gao et al., 1999;
Keele et al., 2006; Nerrienet et al., 2005; Van Heuverswyn et al., 2007)
supports the assertion that immunodeﬁciency viruses causing the
global AIDS pandemic entered the human population in west central
Africa. There, indigenous forest dwellers hunt and butcher non-
human primates, including chimpanzees, and would thus be poten-
tially exposed to retroviruses and other infectious agents in these
animals. Here we report that approximately 4% of Baka pygmies are
heterozygous for a rare allele (R332X) of TRIM5, which encodes one of
the host barriers to cross-species transmission of retroviruses
(Stremlau et al., 2004; Hatziioannou et al., 2004; Keckesova et al.,
2004; Perron et al., 2004; Yap et al., 2004; Song et al., 2005b). The
presence of a stop codon in the TRIM5 R332X allele is predicted to
result in the production of a TRIM5α variant that is truncated in the
B30.2(SPRY) domain. This truncated TRIM5 protein lacks detectable
antiretroviral activity and can exert a dominant-negative effect on the
moderate HIV-1-restricting ability of the wild-type TRIM5α protein.
The TRIM5 R332X allele has not been identiﬁed in previous surveys of
African Americans or South Africans (Javanbakht et al., 2006),
Fig. 5. Association of TRIM5hu R332X and wild-type TRIM5αhu. (A) Cf2Th cells stably expressing wild-type TRIM5α hu-HA and TRIM5hu R332X-V5 were ﬁxed and stained with a
FITC-conjugated anti-HA antibody or a Cy3-conjugated anti-V5 antibody. Representative confocal microscopic images of the Cf2Th cells are shown. Themerged image is shown in the
right panel. (B) 293Tcells were transfectedwith plasmids expressing the indicated TRIM5 variants containing either an HA or a V5 epitope tag. Cell lysateswere precipitated (IP) with
an anti-V5 antibody. The precipitates were then Western blotted (WB) with an anti-V5 antibody (upper panel) or an anti-HA antibody (lower panel).
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in human TRIM5 are apparently rare, whereas a TRIM5 variant (H43Y)
exhibiting modestly decreased antiretroviral activity is quite frequent
in modern humans (Sawyer et al., 2006; Javanbakht et al., 2006).
Species-wide disruption of TRIM5 has occurred in some mammals,
such as dogs (Sawyer et al., 2007).
The observed phenotypes of TRIM5hu R332X are consistent with
expectations based on numerous structure-function studies of
TRIM5α proteins. TRIM5hu R332X is truncated within the v1 variable
region of the B30.2(SPRY) domain, and therefore lacks most of the
beta strands that contribute to the fold of this domain (Seto et al.,
1999; Woo et al., 2006a,b; Yao et al., 2006; Grütter et al., 2006; James
et al., 2007). The remnant of the B30.2(SPRY) domain in TRIMhu
R332X is presumably folded into some non-native structure. TRIM5hu
R332X thus lacks an intact capsid-binding domain, explaining its
defectiveness in retroviral restriction (Stremlau et al., 2004; Perez-
Caballero et al., 2005; Kar et al., 2008; Langelier et al., 2008).
TRIM5α forms dimers, allowing bivalent binding to the retroviral
capsid (Javanbakht et al., 2006; Kar et al., 2008; Langelier et al., 2008).
Because TRIM5hu R332X retains the coiled coil and L2 linker needed
for oligomerization (Javanbakht et al., 2006), TRIM5hu R332X can form
hetero-oligomers with wild-type TRIM5α. As these heterodimers
have only one intact capsid-binding domain, the avidity for capsid is
diminished compared with that of the wild-type TRIM5α dimer. Thus,
as has been previously seen for TRIM5γ and other TRIM5 variants with
deleted B30.2(SPRY) domains (Stremlau et al., 2004; Perez-Caballero
et al., 2005), TRIM5hu R332X exhibits dominant-negative effects on
retroviral restriction when coexpressed with wild-type TRIM5αhu.
Additional investigation will be required to assess the potential
biological consequences of TRIM5 R332X heterozygosity. For example,
the relative levels of expression of the wild-type TRIM5αhu andTRIM5hu R332X proteins in natural target cells would be expected to
modulate the degree to which dominant-negative inactivation of
wild-type TRIM5α function occurs. Although a previous study
(Javanbakht et al., 2006) hinted that some regulatory changes in
TRIM5might affect HIV-1 susceptibility, whether functional decreases
in TRIM5αhu antiretroviral activity resulting from TRIM5hu R332X
expression could predispose to a higher risk of HIV-1 or SIVcpz
infection is unknown. Because of the rarity of the TRIM5 R332X allele,
it is not feasible to perform a case-control study to evaluate the effect
of this polymorphism on susceptibility to HIV-1 infection. In addition
to facilitating the cross-species transmission of SIVcpz from chimpan-
zees to humans, decreased TRIM5 function might also allow
reinfection with HIV-1-like viruses, which promotes the generation
of virus diversity through recombination. Indeed, diverse viruses from
multiple clades and circulating recombinant forms of HIV-1 have been
documented in the inhabitants of rural villages in the equatorial rain
forest and grass ﬁeld regions in Cameroon (Zhong et al., 2003; Konings
et al., 2006). Future studies can explore the intriguing possibility that
host genetic factors particular to the forest-dwelling peoples of west




Administrative and ethical approval to carry out this project was
obtained from the Cameroon Ministry of Public Health and all the
collaborating institutions. From 2001 to 2002, adult volunteers living
in southeastern Cameroon rainforest villages (Fig. 1) participated in a
study of retrovirus molecular epidemiology. For the human genetics
145J.N. Torimiro et al. / Virology 391 (2009) 140–147component of the study, a purposive choice sampling technique
was used to select 95 Baka pygmies (hunter-gatherers) and 32
non-pygmies.
TRIM5 resequencing
The complete exon 8 of human TRIM5, which encodes the B30.2
(SPRY) domain, was resequenced using the following primers: 5′
TCCCTTAGCTGACCTGTTAATTT-3′ and 5′-GCTGTACAGAAGGGGCTGAG-
3′. Samples were resequenced using protocols provided by Applied
Biosystems, and analyzed on an ABI-3730XL instrument.
Cells
Cf2Th canine thymic epithelial cells and 293T cells were obtained
from the American Type Culture Collection and propagated as
recommended.
Plasmids
The wild-type TRIM5αhu cDNA was described previously (Strem-
lau et al., 2004), and corresponds to the major allelic variant in
European Americans and African Americans (Javanbakht et al., 2006).
The R332X mutation was introduced into the wild-type TRIM5 cDNA
by PCR-directed mutagenesis. The TRIM5αhu proteins possess C-
terminal epitope tags derived from either the inﬂuenza virus
hemagglutinin (HA) or the P and V proteins of simian virus 5 (V5).
Creation of cells stably expressing TRIM5 variants
A retroviral vector encoding the wild-type TRIM5αhu-HA protein
was created using the pLPCX plasmid (Stratagene) (Stremlau et al.,
2004). The pLPCX plasmid contains only the amino acid-coding
sequence and not the untranslated region of the TRIM5α cDNA.
Recombinant viruses were produced in 293T cells by cotransfecting
the pLPCX plasmids with the pVPack-GP and pVPack-VSV-G packaging
plasmids (Stratagene). The pVPack-VSV-G plasmid encodes the
vesicular stomatitis virus (VSV) G envelope glycoprotein, which
allows efﬁcient entry into a wide range of vertebrate cells (Yee et al.,
1994). Cf2Th cells stably expressing the wild-type TRIM5αhu-HA
proteins were established by incubation of ∼1×105 cells with
recombinant virus in the presence of 5 μg/ml polybrene. Cells were
selected in 5 μg/ml puromycin.
The R332X human TRIM5 protein with a V5 epitope tag was
expressed using the Viral Power system (Invitrogen) (Diaz-Griffero et
al., 2006). Recombinant lentiviruses were produced according to the
manufacturer's protocol. The resulting virus particles were used to
transduce ∼1×105 Cf2Th cells (or Cf2Th cells expressing wild-type
TRIM5αhu-HA) in the presence of 5 μg/ml polybrene. Cells were
selected in either 5 μg/ml blasticidin for cells expressing R332X
TRIM5αhu-V5, or 5 μg/ml puromycin and 5 μg/ml blasticidin for cells
expressing both wild-type and R332X TRIM5αhu proteins.
TRIM5 protein analysis
Cellular proteins were extracted with radioimmunoprecipitation
assay (RIPA) buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 1% sodium
deoxycholate, 0.1% SDS, 1% Nonidet P-40, 1 mg/ml aprotinin, 2 mg/ml
leupeptin, 1 mg/ml pepstatin A, 100 mg/ml phenylmethylsulfonyl
ﬂuoride). The cell lysates were analyzed by SDS-PAGE (10%
acrylamide), followed by blotting onto nitrocellulose membranes
(Amersham Biosciences). Detection of protein by Western blotting
utilized monoclonal antibodies that are speciﬁcally reactive with the
HA (Roche Applied Science) or V5 (Invitrogen) epitope tags.
Detection of proteins was performed by enhanced chemilumines-
cence (PerkinElmer Life Sciences), using the following secondaryantibodies obtained from Amersham Biosciences: anti-mouse (for
V5) and anti-rat (for HA).
Co-localization experiments
Co-localization was studied as previously described (Javanbakht
et al., 2005). Brieﬂy, cells were grown overnight on 12-mm-
diameter coverslips and ﬁxed in 3.9% paraformaldehyde (Sigma)
in phosphate-buffered saline (PBS, Cellgro) for 30 min. Cells were
washed in PBS, incubated in 0.1 M glycine (Sigma) for 10 min,
washed in PBS, and permeabilized with 0.05% saponin (Sigma) for
30 min. Samples were blocked with 10% donkey serum (Dako,
Carpentaria, CA) for 30 min and incubated for 1 h with antibodies.
The anti-HA ﬂuorescein isothiocyanate-conjugated 3F10 antibody
(Roche Applied Sciences) and anti-V5 Cy3-conjugated antibody
(Sigma) were used to stain HA- or V5-tagged TRIM5α proteins,
respectively. Subsequently, samples were mounted for ﬂuorescence
microscopy by using the ProLong Antifade Kit (Molecular Probes,
Eugene, OR). Images were obtained with a Bio-Rad Radiance 2000
laser scanning confocal microscope with Nikon 60× numerical
aperture 1.4 optics.
Infection with viruses expressing green ﬂuorescent protein
Recombinant viruses (HIV-1-GFP, N-MLV-GFP and B-MLV-GFP)
expressing the humanized Renilla reniformis green ﬂuorescent protein
(GFP) were prepared as previously described (Perron et al., 2004;
Stremlau et al., 2004). The viral stocks were quantiﬁed by measuring
reverse transcriptase activity, as described previously (Rho et al.,
1981). Cf2Th cells expressing the wild-type (wt) and R332X mutant
TRIM5 proteins, or control Cf2Th cells transduced with the empty
pLPCX vector, were incubated with various amounts of the recombi-
nant viruses, as described (Perron et al., 2004; Stremlau et al., 2004).
For infections, 3×104 Cf2Th cells seeded in 24-well plates were
incubated with virus for 24 h. Cells were washed and returned to
culture for 48 h, and then subjected to FACS analysis with a FACScan
(Becton Dickinson).
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